If you've spent any time researching oral semaglutide online, you've probably noticed that the accounts tend to fall into two camps: people who say it was completely fine, and people who describe four bumpy weeks.
The truth is that the first month on oral semaglutide follows a broadly predictable pattern, and knowing that pattern in advance makes it significantly easier to go through.
How it works
Oral semaglutide can't just be swallowed like a regular over-the-counter painkiller. The tablet contains a compound called SNAC that temporarily changes the environment in your stomach, allowing the medication to be absorbed directly through the stomach wall.¹ That process only works correctly under specific conditions:
Completely empty stomach
Exactly 120ml of plain still water
30-minute wait before eating or drinking anything else
Studies have shown that food in the stomach, or even a larger volume of water can significantly reduce absorption.² Oral semaglutide is only absorbed in small amounts to begin with - around 1%.3 So how you take it matters. On days when the routine slips, you may feel the difference.
Week one: the initial phase
Many people notice something in the first few days. Nausea is most commonly reported, typically showing up in the hour or two after taking the tablet, then easing as the morning goes on.³ For most people it's queasiness rather than anything debilitating, but for some it's more noticeable.
Two things you might not be expecting are burping and a slightly metallic or bitter taste in your mouth, usually in that first hour after dosing. These are direct effects of the SNAC compound altering the stomach environment and not a sign anything's gone wrong.¹ They're unique to the oral form, they're temporary, and they tend to fade considerably within the first few weeks.
Fatigue and mild headaches are also common in week one and usually resolve on their own. Your appetite may start shifting earlier than you expect, meaning food is less appealing, and meals are more satisfying before you've finished them.
Weeks two and three: the adjustment period
This is where things either stay manageable or get a little more challenging, and the way in which you take the medication is usually the difference.
Side effects associated with your stomach (feeling sick, stomach pains, burping) were reported as mild to moderate in the majority of participants in the OASIS 1 trial, one of the largest clinical trials of oral semaglutide for weight management.³ The pattern they found is consistent with what commonly reported anecdotally - that the majority of symptoms are most pronounced in the first two to four weeks, then reduce noticeably as the body adjusts.
Constipation can become more of an issue in these middle weeks as gut motility slows. This is because GLP-1 medications slow gastric emptying, which is part of how they work, and the gut takes time to adapt.⁴ Staying hydrated (two to two-and-a-half litres across the day) and keeping moving makes a genuine difference here.
The appetite suppression tends to become more consistent around week two. Rather than fluctuating and being noticeable one day, less so the next, reduced hunger starts feeling like the reliable new normal. Many people describe this as the point where the medication’s effects start becoming more consistent..
Week four: the dose increase
At around week four, the dose steps up from 1.5mg to 4mg. This is a normal part of the titration schedule. Doses are increased gradually to allow the body's GLP-1 receptors to adapt, which is why side effects tend to be less severe than they would be if you started at the full therapeutic dose.⁵
Some people expect a brief return of stomach-related symptoms with the dose increase. This is entirely normal and often settles within a week to ten days, and it's usually shorter and milder than the first adjustment because the body is already adapted.
The good news is that, for many people, burping usually improves noticeably at the four-week mark. Most people find this is around the time the early side effects start feeling like background noise rather than something that requires managing.
What week four actually feels like
By the end of the first month, most people report that the medication has become part of the morning routine rather than an event in itself. The routine is second nature. The nausea is either gone or significantly reduced. And the appetite changes are usually clearly established.
One more thing worth knowing
Hair thinning, known as telogen effluvium, is an uncommon side effect associated with GLP-1 medications. Where it does occur, it's thought to be related more to the physiological stress of rapid weight loss and reduced calorie intake than to the medication itself.⁶ It typically emerges two to four months into treatment if it's going to happen, and generally reverses over time. Getting enough protein matters here, both for hair health and for preserving muscle mass during weight loss.
The numan take
Clinical trials show that side effects of weight loss pills are generally mild, tolerable, and tend to ease over time. If anything during the first month feels more than expected, like if you experience severe or persistent symptoms, then that's a conversation for you to have with your clinician.
References
Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
Bækdal TA, Thomsen M, Kupčová V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314–1323.
Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705–719.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol Metab. 2021;46:101102.
Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4): a randomised, double-blind, placebo-controlled, phase 3a trial. N Engl J Med. 2025;393(11):1077–1087.
Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatol Ther (Heidelb). 2019;9(1):51–70.
Hassan is a specialist clinical pharmacist with a background in digital marketing and business development. He works as a Clinical Copywriter at Numan, leveraging his research and writing abilities to shine a light on the health complications affecting men and women.
